Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 525

Sort by

Sort Order Select

Journal Articles

Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?

Mark Dalgetty, Jorge Cortes

Blood blood.2024027944.

https://doi.org/10.1182/blood.2024027944

Published: 2025

Journal Articles

Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors

Lukas Veltmaat, Jorge Cortes

Blood (2024) 143 (10): 858–865.

https://doi.org/10.1182/blood.2023022403

Published: 2024

Journal Articles

Serum Ferritin Levels Prior to Mobilization and Collection May Not Influence Stem Cell Yield

Charles Weeks, Danielle Bradshaw, Sujith Abbagoni, Mohammad Mian, Sarah Jimenez, Courtney Corley, Amany R. Keruakous, Ayushi Chauhan, Locke Johnson Bryan, Jorge Cortes, Anand Jillella, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2023-191204

Published: 2023

Journal Articles

The Overuse of C. Difficile T esting Among Autologous Transplant Patients with Melphalan Conditioning: A Single Center Experience

James Dickey, Meaghan Standridge, Shreya Desai, Isabela Pavkov, Stacy Bedore, Priyanshu Nain, Mohammad Mian, Ayushi Chauhan, Amany R. Keruakous, Locke Johnson Bryan, Anand Jillella, Jorge Cortes, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 7065.

https://doi.org/10.1182/blood-2023-191226

Published: 2023

Journal Articles

Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)

Jorge Cortes, Jay Yang, Sangmin Lee, Shira N. Dinner, Eunice S. Wang, Maria R. Baer, William B. Donnellan, Justin M. Watts

Blood (2023) 142 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2023-187404

Published: 2023

Journal Articles

Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia

Eunice S. Wang, Brian A. Jonas, Justin M. Watts, Joseph Jurcic, P. Brent Ferrell, Jr., Shira N. Dinner, Jay Yang, Karen Seiter, Alice Mims, William B. Donnellan, William Blum, Jorge Cortes

Blood (2023) 142 (Supplement 1): 6047.

https://doi.org/10.1182/blood-2023-187584

Published: 2023

Journal Articles

ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment

Ehab L. Atallah, Michael Mauro, Koji Sasaki, Moshe Levy, Paul B. Koller, Daisy Yang, Dramane Laine, John Sabo, Ennan GU, Jorge Cortes

Blood (2023) 142 (Supplement 1): 6389.

https://doi.org/10.1182/blood-2023-186974

Published: 2023

Journal Articles

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, Jorge Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Susanne Saussele, Francois Mahon, Tim H. Brümmendorf, Shruti Kapoor, Tracey McCulloch, Peter Schuld, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 6388.

https://doi.org/10.1182/blood-2023-186773

Published: 2023

Journal Articles

Are Pivotal CART Trials Representative of Population at Risk?

Anvay Shah, Vamsi K. Kota, Mycal Casey, Lorriane Odhiambo, Vishrut Shah, KM Islam, Anand Jillella, Locke Johnson Bryan, Amany R. Keruakous, Ayushi Chauhan, Jorge Cortes

Blood (2023) 142 (Supplement 1): 5884.

https://doi.org/10.1182/blood-2023-191122

Published: 2023

Journal Articles

Real-World Outcomes for Primary CNS Lymphoma from a Single Academic Institution: The Augusta Experience

Michael Chahin, Sruthi Dontu, Amany R. Keruakous, Anand Jillella, Jorge Cortes, Vamsi K. Kota, Locke Johnson Bryan, Ayushi Chauhan

Blood (2023) 142 (Supplement 1): 6312.

https://doi.org/10.1182/blood-2023-189357

Published: 2023

Journal Articles

Financial Trends of AML Patients over the Past Decade

Mark Dalgetty, Mahran Shoukier, Danielle Bradshaw, Faizan Boghani, Sruthi Athota, Anvay Shah, Meaghan Standridge, Michael Stokes, Mohammad Mian, Ayushi Chauhan, Amany R. Keruakous, Locke Johnson Bryan, Jorge Cortes, Anand Jillella, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 5876.

https://doi.org/10.1182/blood-2023-191103

Published: 2023

Journal Articles

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Blood (2023) 142 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2023-187744

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Timothy P Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Torres Cardoso, Jomy Jose, Monali Sura, Jorge Cortes

Blood (2023) 142 (Supplement 1): 866.

https://doi.org/10.1182/blood-2023-182100

Published: 2023

Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Blood (2023) 142 (Supplement 1): 450.

https://doi.org/10.1182/blood-2023-187322

Published: 2023

Journal Articles

Eliminating Racial Disparities Among Transplant Patients in Multiple Myeloma after Referral to a Tertiary Center

Shreya Desai, Meaghan Standridge, Danielle Bradshaw, Mohammad Mian, Ayushi Chauhan, Amany R. Keruakous, Locke Johnson Bryan, Jorge Cortes, Anand Jillella, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 6659.

https://doi.org/10.1182/blood-2023-190828

Published: 2023

Journal Articles

Disparities in Phase 3 Leukemia Trials from the Last Decade: A Long Way to Go

Andres Noyola-Perez, Alejandra J. Osuna-Corrales, Manali I. Patel, Jorge Cortes, Lillian Sung, Juan C. Angulo-Lozano, Perla R. Colunga-Pedraza, David Gomez-Almaguer, Guillermo José Ruiz-Arguelles, Andres Gomez-De Leon

Blood (2023) 142 (Supplement 1): 494.

https://doi.org/10.1182/blood-2023-189576

Published: 2023

Journal Articles

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Jorge Cortes, Joseph Jurcic, Maria R. Baer, William Blum, P. Brent Ferrell, Jr., Brian A. Jonas, Sangmin Lee, Alice Mims, Shyam Ajay Patel, Gary J. Schiller, Jay Yang, Justin M. Watts

Blood (2023) 142 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2023-187861

Published: 2023

Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Blood (2023) 142 (Supplement 1): 4536.

https://doi.org/10.1182/blood-2023-186854

Published: 2023

Journal Articles

Therapy Related Multiple Myeloma: A Distinct Entity

Meaghan Standridge, Shreya Desai, Sujith Abbagoni, Sabrina Matosz, Danielle Bradshaw, Mohammad Mian, Mohommed Syam, Vamsi K. Kota, Jorge Cortes, Amany R. Keruakous, Ayushi Chauhan, Locke Johnson Bryan, Anand Jillella

Blood (2023) 142 (Supplement 1): 6657.

https://doi.org/10.1182/blood-2023-190298

Published: 2023

NARROW

Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?

Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors

Serum Ferritin Levels Prior to Mobilization and Collection May Not Influence Stem Cell Yield

The Overuse of C. Difficile T esting Among Autologous Transplant Patients with Melphalan Conditioning: A Single Center Experience

Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)

Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia

ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Are Pivotal CART Trials Representative of Population at Risk?

Real-World Outcomes for Primary CNS Lymphoma from a Single Academic Institution: The Augusta Experience

Financial Trends of AML Patients over the Past Decade

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Eliminating Racial Disparities Among Transplant Patients in Multiple Myeloma after Referral to a Tertiary Center

Disparities in Phase 3 Leukemia Trials from the Last Decade: A Long Way to Go

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Therapy Related Multiple Myeloma: A Distinct Entity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only